NCT06242470 A Study of MGC026 in Participants With Advanced Solid Tumors
| NCT ID | NCT06242470 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | MacroGenics |
| Condition | Advanced Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-03-06 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 250 participants in total. It began in 2024-03-06 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Eligibility Criteria
Inclusion Criteria: * Adults ≥ 18 years old, able to provide informed consent * Adequate performance and laboratory parameters * Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible * Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer. * Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible. * Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026. * Not pregnant or breastfeeding. Exclusion Criteria: * Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures. * Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \< 6), or carcinoma in situ. * Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment. * Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals. * Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload. * Prior autologous or allogeneic stem cell or solid organ transplant. * Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders. * Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration. * Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction. * Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome. * History of primary immunodeficiency. * Major trauma or major surgery within 4 weeks of first study drug administration. * Known hypersensitivity to recombinant proteins.
Contact & Investigator
Denise Casey, MD
STUDY DIRECTOR
MacroGenics
Frequently Asked Questions
Who can join the NCT06242470 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06242470 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06242470 currently recruiting?
Yes, NCT06242470 is actively recruiting participants. Contact the research team at info@macrogenics.com for enrollment information.
Where is the NCT06242470 trial being conducted?
This trial is being conducted at Los Angeles, United States, Grand Rapids, United States, Lake Success, United States, Portland, United States and 8 additional locations.
Who is sponsoring the NCT06242470 clinical trial?
NCT06242470 is sponsored by MacroGenics. The principal investigator is Denise Casey, MD at MacroGenics. The trial plans to enroll 250 participants.